Patients with rheumatoid arthritis (RA) and their rheumatology healthcare providers commonly face discordance as many patients report a higher disease activity rate than their providers.
Patients with rheumatoid arthritis (RA) and their rheumatology healthcare providers commonly face discordance as many patients report a higher disease activity rate than their providers.
A study published in Arthritis Research & Therapy examined the discordance between patients with RA and their healthcare providers by conducting an observational study of RA patients at the Mayo Clinic in Rochester, Minnesota. A total of 350 patients diagnosed with RA or inflammatory polyarthritis were identified by the research coordinator. These patients were seen for an appointment in the out-patient rheumatology practice within 4 weeks of screening. Additionally, electronic medical records were obtained to determine the eligible participants and to assess the disease activity, clinical characteristics, comorbidities, and medications.
“Many studies have sought to identify the determinants of patient-provider discordance in RA. Previous cross-sectional studies have reported that patient-reported measures of pain intensity, fatigue, depression, physical function, and health-related quality of life are key correlates of discordance,” the authors wrote. “…Therefore, this study aimed to delve deeper into the clinical correlates of patient-provider discordance by explicating the potential etiologic domains underlying the adverse health status of patients.”
The data suggested that patient-provider discordance affected 32.5% of the 350 consecutive patients. Of the population, 29.5% were found to have rater a higher disease activity than their providers, while only 3.1% rated a lower disease activity than their providers. Also, positive discordance was related to negative rheumatoid factors, anticyclic citrullinated peptide antibodies, lack joint erosions, depression, and the use of opioids, antidepressants, anxiolytics, or fibromyalgia medications. Overall, the rate of patient-provider discordance was determined to be at 33%, although a significant percentage of these patients rate their condition as more severe than their providers.
“The findings suggest that routine measurement of patient-reported outcomes could help identify the central drivers of adverse health status apart from inflammatory disease activity and thereby could suggest potential interventions,” the authors wrote.
These findings should promote the development of a standardized approach and assessment to evaluate and manage rheumatoid arthritis, but until this development, providers should moniter the impact of a patient’s health status and treat the common comorbidities like depression, the authors suggested.
Lack of Mutations Associated With Favorable Prognosis in MPN-U
April 25th 2024While the Dynamic International Prognostic Scoring System and bone marrow blasts may predict overall survival, the lack of certain mutations is also associated with a better prognosis for myeloproliferative neoplasm, unclassifiable (MPN-U).
Read More
HOPE-CAT Can Identify Maternal Cardiovascular Risk 2 Months Earlier Than Doctors, Study Says
April 25th 2024In a retrospective study, the machine learning tool was able to screen for potential risks of cardiovascular disease nearly 60 days before the patient's medical record showed any signs of a related condition or before they were officially diagnosed or treated for it.
Read More
Data Back Neoadjuvant Combo vs Chemo Alone for Early-Stage NSCLC
April 24th 2024For patients with early-stage non–small cell lung cancer (NSCLC), combining neoadjuvant immune checkpoint inhibitors and platinum-based chemotherapy improves 2-year outcomes over chemotherapy alone, suggest findings of an extensive literature review and meta-analysis.
Read More